Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Stitch Fix Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while Stitch Fix Inc trades at $3.63 (market cap $475.00M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 84× Stitch Fix Inc's market cap, and Stitch Fix Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SFIX | |
|---|---|---|
Market Cap | $39.89B | $475.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $5.83 |
52-Week Low | $278.09 | $3.06 |
Enterprise Value | $38.15B | $362.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Stitch Fix (SFIX) trades at $3.56, up 1.14% today, showing signs of a potential turnaround despite technical bearish signals. The company has demonstrated improving fundamentals with three consecutive quarterly earnings beats and narrowing losses, while revenue has stabilized around $1.3 billion. Recent news highlights AI-driven personalization initiatives and growing client spending, though the stock remains near historic lows with a bearish technical outlook.
The outlook suggests cautious optimism as SFIX executes its turnaround strategy, with analyst consensus pointing to 33% upside potential. Key risks include ongoing net losses, competitive pressures in online retail, and execution challenges in maintaining client growth momentum. The stock presents a high-risk opportunity for investors betting on the company's AI-driven personalization strategy and margin improvement trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
